A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in Brazil. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2019-05-13.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 95th largest by enrollment, is one of 9 that started in 2013, is one of 65 in phase 3, and was the 66th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 122nd largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2013, is one of 85 in phase 3, and was the 150th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week WA19926 (NCT01007435) core study. Eligible participants will be those who are expected to benefit from the study medicine based on the investigator's discretion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
Drug: Tocilizumab
Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
Also known as: RoActemra, Actemra
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. An SAE can be a) fatal, b) life-threatening, c) requires/prolongs hospitalization, d) results in persistent/significant incapacity/disability, e) results in congenital anomaly/birth defect or f) is considered as a significant medical event by the investigator.
Time frame: Baseline up to approximately 104 weeks
Percentage of Participants With TEAEs of Special Interest
An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. Nine categories of AE of special interest are identified for tocilizumab which includes a) serious/medically significant infections, b) myocardial infarction/acute coronary syndrome, c) gastrointestinal perforations, d) malignancies, e) anaphylaxis/hypersensitivity reactions, f) demyelinating disorders, g) stroke, h) serious and/or medically significant bleeding events, and i) serious/medically significant hepatic events. Data reported is an average of the nine categories.
Time frame: Baseline up to approximately 104 weeks
Percentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation
An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started.
Time frame: Baseline up to approximately 104 weeks
Change From Baseline (CFB) in Disease Activity Score 28 Using Erythrocyte Sedimentation Rate (DAS28-ESR) at Specified Time Points
The DAS28-ESR is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and general health (GH) (patient global assessment of disease activity \[PGA\] using visual analog scale \[VAS\], range 1-100 millimeters \[mm\]) (higher scores indicate higher disease activity). DAS28-ESR is calculated according to the following formula: DAS28-ESR equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm \[ln\] ESR in mm/h) + (0.014\*GH in mm VAS). DAS28-ESR scale is transformed and ranges from 0 to 10. A negative CFB indicated improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
CFB in Simplified Disease Activity Index (SDAI) Score at Specified Time Points
The SDAI is a combined index for measuring disease activity. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), physician global assessment (PhGA) and PGA of disease activity, both scored 0 to 10 centimeters (cm) as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal is less than (\<) 1 mg/dL. SDAI is calculated according to the following formula: SDAI = TJC + SJC + PhGA + PGA + CRP. SDAI ranges from 0 to 86. A negative CFB indicated improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
CFB in Swollen Joint Count (SJC) at Specified Time Points
For SJC, a total of 66 joints are assessed. The presence of a swollen joint is scored as 1 and absence as 0. Total score is calculated by adding the scores, which ranges from 0 (best possible score or no swollen joint) to 66 (worse possible score or all swollen joints). Lower scores indicated no swollen joint and higher scores indicated worsening swollen joints.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
CFB in Tender Joint Count (TJC) at Specified Time Points
The number of tender joints is recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 68 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
Percentage of Participants Reaching Clinical Remission (DAS28-ESR Score Less Than [<] 2.6 and/or SDAI Score Less Than or Equal to [</=] 3.3) Among Participants for Whom Tocilizumab Treatment Was Discontinued
Remission: DAS28-ESR score \<2.6 and SDAI score \</=3.3. DAS28-ESR index included SJC and TJC, both scored 0-28, as well as APR determined as ESR in mm/hr, and GH (ranges 1-100 mm; higher scores=higher disease activity). DAS28=(0.56\*√TJC)+(0.28\*√SJC) +(0.70\*ln ESR) +(0.014\*GH). DAS28-ESR scale is transformed and ranges from 0 to 10. Negative CFB indicated improvement. DAS28 \>2.6 (clinical remission); DAS28 2.6 to 3.2 (low disease activity); DAS28 \>3.2 to 5.1 = moderate to high disease activity. SDAI is sum of TJC and SJC (both scored 0-28), PhGA and PGA of disease activity (both scored 0 to 10 cm as assessed by VAS, higher scores=higher disease activity), and CRP in mg/dL where normal is \<1 mg/dL. SDAI=TJC + SJC + PhGA + PGA + CRP. SDAI ranged from 0 to 86. A negative CFB indicated improvement. SDAI \<=3.3 (clinical remission), \>3.4 to 11 (low disease activity) \>11 to 26 (moderate disease activity), and \>26 = (high/severe disease activity).
Time frame: Baseline up to approximately 104 weeks
Time to RA Crisis Among Participants Who Discontinued After Clinical Remission
RA crisis is any worsening of participant disease acitivity that, in the opinion of the investigator, required intensified treatment other than supportive therapy, and may have included restart of the treatment with the study drug. Time to RA crisis is defined as the period of remission without drug until the RA crisis documentation.
Time frame: Baseline up to approximately 104 weeks
CFB in PGA of Disease Activity Using VAS Score at Specified Time Points
PGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative CFB indicated improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
CFB in PGA of Pain Using VAS Score at Specified Time Points
PGA of pain is assessed on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm, and is described as "unbearable pain". A negative change indicated improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
CFB in PhGA of Disease Activity Using VAS Score at Specified Time Points
PhGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
CFB in Health Assessment Questionnaire-Disease Index (HAQ-DI) Score at Specified Time Points
HAQ-DI is a self-reported participant questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Total score for HAQ-DI is the sum of all questions and ranges from 0 = without any difficulty to 60 = unable to do. A negative CFB indicates improvement.
Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, early withdrawal (up to 104 weeks), follow-up 1 (8 weeks after the last visit or discontinuation; 112 weeks), follow-up 2 (16 weeks after the last visit or discontinuation; 120 weeks)
| Milestone | Tocilizumab |
|---|---|
| Started | 23 |
| Treated | 21 |
| Completed | 19 |
| Not completed | 4 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 1 |
| Withdrew: Not treated | 2 |
An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. An SAE can be a) fatal, b) life-threatening, c) requires/prolongs hospitalization, d) results in persistent/significant incapacity/disability, e) results in congenital anomaly/birth defect or f) is considered as a significant medical event by the investigator.
| percentage of participants | Tocilizumab |
|---|---|
| TEAEs | 95.2 |
| SAEs | 9.5 |
An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started. Nine categories of AE of special interest are identified for tocilizumab which includes a) serious/medically significant infections, b) myocardial infarction/acute coronary syndrome, c) gastrointestinal perforations, d) malignancies, e) anaphylaxis/hypersensitivity reactions, f) demyelinating disorders, g) stroke, h) serious and/or medically significant bleeding events, and i) serious/medically significant hepatic events. Data reported is an average of the nine categories.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With TEAEs of Special Interest | 95.2 |
An AE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporarily associated with use of study drug, regardless of its relation to study drug. A TEAE is an AE that occurs only once treatment has started.
| percentage of participants | Tocilizumab |
|---|---|
| TEAEs leading to study drug discontinuation | 4.8 |
| TEAEs leading to dose modification | 28.6 |
The DAS28-ESR is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and general health (GH) (patient global assessment of disease activity \[PGA\] using visual analog scale \[VAS\], range 1-100 millimeters \[mm\]) (higher scores indicate higher disease activity). DAS28-ESR is calculated according to the following formula: DAS28-ESR equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm \[ln\] ESR in mm/h) + (0.014\*GH in mm VAS). DAS28-ESR scale is transformed and ranges from 0 to 10. A negative CFB indicated improvement.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=21) | 2.4 ± 1.76 |
| CFB at Week 12 (n=19) | -0.6 ± 1.6 |
| CFB at Week 24 (n=21) | -0.6 ± 1.7 |
| CFB at Week 36 (n=19) | -0.5 ± 1.3 |
| CFB at Week 48 (n=20) | -0.6 ± 1.9 |
| CFB at Week 56 (n=19) | -0.5 ± 1.7 |
| CFB at Week 68 (n=20) | -0.4 ± 2.0 |
| CFB at Week 80 (n=21) | 0.3 ± 1.9 |
| CFB at Week 92 (n=18) | -0.2 ± 1.5 |
| CFB at Week 104 (n=16) | -0.7 ± 1.3 |
| CFB at Early withdrawal (n=1) | -0.3 ± NA |
| CFB at Follow-up visit 1 (n=16) | 0.6 ± 2.1 |
| CFB at Follow-up visit 2 (n=14) | 1.7 ± 2.0 |
The SDAI is a combined index for measuring disease activity. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), physician global assessment (PhGA) and PGA of disease activity, both scored 0 to 10 centimeters (cm) as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal is less than (\<) 1 mg/dL. SDAI is calculated according to the following formula: SDAI = TJC + SJC + PhGA + PGA + CRP. SDAI ranges from 0 to 86. A negative CFB indicated improvement.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=21) | 9.5 ± 11.84 |
| CFB at Week 12 (n=20) | -2.4 ± 7.75 |
| CFB at Week 24 (n=21) | -2.7 ± 11.46 |
| CFB at Week 36 (n=20) | -2.8 ± 9.85 |
| CFB at Week 48 (n=20) | -3.0 ± 12.71 |
| CFB at Week 56 (n=20) | -3.2 ± 11.09 |
| CFB at Week 68 (n=20) | -0.6 ± 18.1 |
| CFB at Week 80 (n=21) | 0.9 ± 13.92 |
| CFB at Week 92 (n=19) | -1.1 ± 9.47 |
| CFB at Week 104 (n=19) | -1.4 ± 7.6 |
| CFB at Early withdrawal (n=1) | -0.3 ± NA |
| CFB at Follow-up visit 1 (n=19) | 2.0 ± 12.36 |
| CFB at Follow-up visit 2 (n=14) | 9.5 ± 16.71 |
For SJC, a total of 66 joints are assessed. The presence of a swollen joint is scored as 1 and absence as 0. Total score is calculated by adding the scores, which ranges from 0 (best possible score or no swollen joint) to 66 (worse possible score or all swollen joints). Lower scores indicated no swollen joint and higher scores indicated worsening swollen joints.
| swollen joints | Tocilizumab |
|---|---|
| Baseline (n=21) | 0.8 ± 1.7 |
| CFB at Week 12 (n=6) | -1.3 ± 1.37 |
| CFB at Week 24 (n=7) | -1.6 ± 1.81 |
| CFB at Week 36 (n=6) | -1.5 ± 2.81 |
| CFB at Week 48 (n=7) | -0.9 ± 3.48 |
| CFB at Week 56 (n=6) | -1.8 ± 2.56 |
| CFB at Week 68 (n=7) | -2.0 ± 2.38 |
| CFB at Week 80 (n=7) | 1.1 ± 5.49 |
| CFB at Week 92 (n=6) | 1.7 ± 5.32 |
| CFB at Week 104 (n=6) | 1.2 ± 3.82 |
| CFB at Follow-up visit 1 (n=6) | -1.3 ± 1.37 |
| CFB at Follow-up visit 2 (n=3) | -1.0 ± 0.0 |
The number of tender joints is recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 68 joints and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.
| tender joints | Tocilizumab |
|---|---|
| Baseline (n=21) | 5.8 ± 8.57 |
| CFB at Week 12 (n=13) | -3.1 ± 8.95 |
| CFB at Week 24 (n=14) | -4.8 ± 10.39 |
| CFB at Week 36 (n=14) | -5.4 ± 8.35 |
| CFB at Week 48 (n=14) | -5.9 ± 8.4 |
| CFB at Week 56 (n=14) | -6.0 ± 8.41 |
| CFB at Week 68 (n=13) | -2.3 ± 16.51 |
| CFB at Week 80 (n=14) | -3.5 ± 11.65 |
| CFB at Week 92 (n=12) | -3.6 ± 12.42 |
| CFB at Week 104 (n=12) | -4.3 ± 9.98 |
| CFB at Early withdrawal (n=1) | 0.0 ± NA |
| CFB at Follow-up visit 1 (n=12) | 0.0 ± 0.0 |
| CFB at Follow-up visit 2 (n=9) | 2.4 ± 8.85 |
Remission: DAS28-ESR score \<2.6 and SDAI score \</=3.3. DAS28-ESR index included SJC and TJC, both scored 0-28, as well as APR determined as ESR in mm/hr, and GH (ranges 1-100 mm; higher scores=higher disease activity). DAS28=(0.56\*√TJC)+(0.28\*√SJC) +(0.70\*ln ESR) +(0.014\*GH). DAS28-ESR scale is transformed and ranges from 0 to 10. Negative CFB indicated improvement. DAS28 \>2.6 (clinical remission); DAS28 2.6 to 3.2 (low disease activity); DAS28 \>3.2 to 5.1 = moderate to high disease activity. SDAI is sum of TJC and SJC (both scored 0-28), PhGA and PGA of disease activity (both scored 0 to 10 cm as assessed by VAS, higher scores=higher disease activity), and CRP in mg/dL where normal is \<1 mg/dL. SDAI=TJC + SJC + PhGA + PGA + CRP. SDAI ranged from 0 to 86. A negative CFB indicated improvement. SDAI \<=3.3 (clinical remission), \>3.4 to 11 (low disease activity) \>11 to 26 (moderate disease activity), and \>26 = (high/severe disease activity).
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of participants achieved DAS28-ESR <2.6 | 100 |
| Percentage of participants achieved SDAI</=3.3 | 100 |
RA crisis is any worsening of participant disease acitivity that, in the opinion of the investigator, required intensified treatment other than supportive therapy, and may have included restart of the treatment with the study drug. Time to RA crisis is defined as the period of remission without drug until the RA crisis documentation.
| days | Tocilizumab |
|---|---|
| Time to RA Crisis Among Participants Who Discontinued After Clinical Remission | 135.3 ± 53.73 |
PGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative CFB indicated improvement.
| mm | Tocilizumab |
|---|---|
| Baseline (n=21) | 26.5 ± 19.90 |
| CFB at Week 12 (n=20) | -0.3 ± 16.1 |
| CFB at Week 24 (n=21) | 2.5 ± 23.2 |
| CFB at Week 36 (n=20) | 2.0 ± 18.5 |
| CFB at Week 48 (n=20) | 0.4 ± 25.8 |
| CFB at Week 56 (n=20) | -0.5 ± 22.1 |
| CFB at Week 68 (n=20) | 1.3 ± 27.0 |
| CFB at Week 80 (n=21) | 6.2 ± 27.5 |
| CFB at Week 92 (n=19) | 3.5 ± 21.6 |
| CFB at Week 104 (n=19) | 5.1 ± 18.4 |
| CFB at Early withdrawal (n=1) | 6.0 ± NA |
| CFB at Follow-up visit 1 (n=17) | 4.9 ± 22.3 |
| CFB at Follow-up visit 2 (n=14) | 11.0 ± 29.4 |
PGA of pain is assessed on a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm, and is described as "unbearable pain". A negative change indicated improvement.
| mm | Tocilizumab |
|---|---|
| Baseline (n=21) | 22.3 ± 21.76 |
| CFB at Week 12 (n=20) | 2.5 ± 14.1 |
| CFB at Week 24 (n=21) | 5.0 ± 27.7 |
| CFB at Week 36 (n=20) | 3.6 ± 18.5 |
| CFB at Week 48 (n=20) | 0.6 ± 26.4 |
| CFB at Week 56 (n=20) | 1.0 ± 20.0 |
| CFB at Week 68 (n=20) | 3.7 ± 26.4 |
| CFB at Week 80 (n=21) | 7.5 ± 28.9 |
| CFB at Week 92 (n=19) | 2.8 ± 23.4 |
| CFB at Week 104 (n=19) | 5.8 ± 19.8 |
| CFB at Early withdrawal (n=1) | 8.0 ± NA |
| CFB at Follow-up visit 1 (n=17) | 7.8 ± 24.4 |
| CFB at Follow-up visit 2 (n=14) | 13.6 ± 29.0 |
PhGA of disease activity is assessed on a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
| mm | Tocilizumab |
|---|---|
| Baseline (n=21) | 7.9 ± 11.13 |
| CFB at Week 12 (n=20) | -1.0 ± 7.3 |
| CFB at Week 24 (n=21) | -0.8 ± 7.7 |
| CFB at Week 36 (n=20) | -1.0 ± 8.3 |
| CFB at Week 48 (n=20) | 0.8 ± 13.1 |
| CFB at Week 56 (n=20) | -2.2 ± 9.6 |
| CFB at Week 68 (n=20) | 1.5 ± 18.1 |
| CFB at Week 80 (n=21) | 7.6 ± 21.3 |
| CFB at Week 92 (n=19) | 4.1 ± 13.3 |
| CFB at Week 104 (n=19) | 5.1 ± 12.2 |
| CFB at Early withdrawal (n=1) | -1.0 ± NA |
| CFB at Follow-up visit 1 (n=19) | 3.4 ± 9.0 |
| CFB at Follow-up visit 2 (n=14) | 9.1 ± 17.3 |
HAQ-DI is a self-reported participant questionnaire specific for RA. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Total score for HAQ-DI is the sum of all questions and ranges from 0 = without any difficulty to 60 = unable to do. A negative CFB indicates improvement.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=21) | 4.38 ± 5.463 |
| CFB at Week 12 (n=20) | 1.60 ± 7.155 |
| CFB at Week 24 (n=21) | -0.10 ± 4.560 |
| CFB at Week 36 (n=20) | 0.05 ± 4.419 |
| CFB at Week 48 (n=20) | -1.05 ± 4.199 |
| CFB at Week 56 (n=20) | -0.65 ± 4.258 |
| CFB at Week 68 (n=20) | -0.40 ± 7.373 |
| CFB at Week 80 (n=21) | 2.57 ± 10.03 |
| CFB at Week 92 (n=19) | 1.21 ± 5.855 |
| CFB at Week 104 (n=19) | 0.21 ± 5.473 |
| CFB at Early withdrawal (n=1) | -1.00 ± NA |
| CFB at Follow-up visit 1 (n=17) | 0.94 ± 5.226 |
| CFB at Follow-up visit 2 (n=14) | 3.64 ± 6.344 |
Collected over Baseline up to approximately 104 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 2/21 (9.5%) | 20/21 (95.2%) |
| Event | Tocilizumab |
|---|---|
| Vaginal bleedingReproductive system and breast disorders | 1/21 |
| BronchopneumoniaRespiratory, thoracic and mediastinal disorders | 1/21 |
| Cardiac arrhythimiaCardiac disorders | 1/21 |
| Event | Tocilizumab |
|---|---|
| Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders | 9/21 |
| DyslipidaemiaMetabolism and nutrition disorders | 5/21 |
| Upper respiratory tract infectionInfections and infestations | 4/21 |
| TracheobronchitisRespiratory, thoracic and mediastinal disorders | 3/21 |
| Vaginitis BacterialInfections and infestations | 2/21 |
| Transaminases IncreasedInvestigations | 2/21 |
| Urinary Tract InfectionRenal and urinary disorders | 2/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/21 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 2/21 |
| SinusitisRespiratory, thoracic and mediastinal disorders | 2/21 |
Intent to treat (ITT) population included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 52.5 ± 9.18 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 15 |
| Male | 6 |
Ran from Dec 2013 to primary completion in May 2016, 29 months.
Results were first posted in May 2019, 3 years after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 29 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab